List of Excipients in Branded Drug BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

Generic Drugs Containing BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	buprenorphine hydrochloride and naloxone hydrochloride dihydrate	0054-0188	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	buprenorphine hydrochloride and naloxone hydrochloride dihydrate	0054-0188	FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc	buprenorphine hydrochloride and naloxone hydrochloride dihydrate	0054-0188	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	buprenorphine hydrochloride and naloxone hydrochloride dihydrate	0054-0188	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	buprenorphine hydrochloride and naloxone hydrochloride dihydrate	0054-0188	MANNITOL

What are the Most Frequently-Used Excipients in BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE?

# Of NDCs	Excipient
6	ACESULFAME POTASSIUM
6	ALUMINUM OXIDE
21	ANHYDROUS CITRIC ACID
6	ANHYDROUS LACTOSE
7	CROSPOVIDONE

Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate: Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Buprenorphine hydrochloride and naloxone hydrochloride dihydrate is the active pharmaceutical ingredient combination used in sublingual and buccal opioid-use-disorder products, led by Indivior’s Suboxone. Commercial opportunities are concentrated in generic sublingual films, differentiated tablets, improved taste and dissolution, abuse-deterrent delivery systems, and lower-cost manufacturing.

The formulation challenge is balancing rapid transmucosal delivery of buprenorphine with low systemic naloxone exposure under intended sublingual use. Excipients control film strength, wetting, dissolution, taste, dose uniformity, moisture protection, and manufacturing yield. The strongest product strategies use excipients that improve performance without creating new bioequivalence or safety barriers.

What products contain buprenorphine hydrochloride and naloxone hydrochloride dihydrate?

The combination is marketed primarily as sublingual films and sublingual tablets. Buprenorphine is the pharmacologically active opioid partial agonist. Naloxone is included to discourage intravenous misuse because naloxone has limited bioavailability when used correctly under the tongue but can antagonize opioid effects if injected.

Product	Manufacturer	Dosage form	Common strengths	Regulatory status
Suboxone sublingual film	Indivior	Sublingual film	2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg	FDA-approved NDA 022410
Suboxone sublingual tablet	Indivior	Sublingual tablet	2 mg/0.5 mg, 8 mg/2 mg	Earlier FDA-approved product; commercial focus shifted to film
Zubsolv	BDSI, now associated with Sandoz commercialization	Sublingual tablet	0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8.6 mg/2.1 mg, 11.4 mg/2.9 mg	FDA-approved NDA 204242
Generic buprenorphine/naloxone film and tablets	Multiple manufacturers	Sublingual film or tablet	Generally 2 mg/0.5 mg and 8 mg/2 mg equivalents	Approved through ANDA pathways

Strengths are generally expressed as buprenorphine base and naloxone base equivalents, even though the formulation uses hydrochloride salt forms. The hydrate state of naloxone hydrochloride affects molecular weight, assay calculations, water content, and raw-material specifications.

Which excipients are used in Suboxone and competing products?

The primary commercial excipient systems fall into two groups: polymeric film matrices and directly compressible or molded tablet systems.

Suboxone sublingual film excipients

The Suboxone film label identifies excipients including maltitol, hydroxypropyl cellulose, polyethylene oxide, citric acid, sodium citrate, acesulfame potassium, flavoring agents, and coloring agents. The exact composition is product-specific and may differ by strength or manufacturing presentation.[1]

Excipient class	Representative excipient	Formulation function
Film-forming polymer	Hydroxypropyl cellulose	Film structure, flexibility, adhesion
Matrix polymer	Polyethylene oxide	Viscosity, residence time, film integrity
Bulking agent and plasticity modifier	Maltitol	Mouthfeel, solids content, flexibility, taste masking
Buffer system	Citric acid and sodium citrate	Microenvironmental pH and dissolution control
Sweetener	Acesulfame potassium	Taste masking
Flavor system	Product-specific flavor	Reduction of bitter and metallic taste
Colorant	Product-specific colorant	Identification and product appearance

A film formulation must maintain content uniformity at low total drug loading while producing a dry sheet that can be slit, die-cut, packaged, and dissolved consistently. The polymer-to-plasticizer ratio is central to commercial performance. Excess polymer can slow drug release and produce a gummy residue. Insufficient polymer can cause brittle films, edge cracking, dose loss, and poor packaging performance.

Sublingual tablet excipients

Sublingual tablets typically use lactose or mannitol as diluents, povidone as a binder, crospovidone or starch as a disintegrant, magnesium stearate as a lubricant, and sweeteners or flavors for palatability. Zubsolv uses a specialized tablet platform with excipients selected for rapid disintegration and taste control.[2,3]

Excipient class	Typical examples	Commercial objective
Diluent	Mannitol, lactose monohydrate, microcrystalline cellulose	Tablet mass and manufacturability
Binder	Povidone	Mechanical strength
Disintegrant	Crospovidone, starch	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and tooling protection
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Sweetener	Sucralose, acesulfame potassium	Taste masking
Flavor	Citrus, mint, or proprietary flavor	Patient acceptability

Tablet platforms generally have simpler manufacturing than films, but they can produce more variable residence time, higher tablet mass, and greater risk of swallowing before complete sublingual dissolution.

How should excipients be selected for this combination?

Excipient selection should be based on five performance requirements: rapid dissolution, sublingual adhesion, taste masking, dose uniformity, and moisture stability.

1. Control sublingual dissolution

The formulation should release buprenorphine rapidly enough to support practical dosing while avoiding excessive swallowing. Hydroxypropyl cellulose and polyethylene oxide can provide film cohesion and mucosal residence, but higher polymer loading may delay release.

Key development variables include:

• Polymer molecular weight and substitution grade
• Film thickness
• Residual moisture
• Drug particle size and dispersion
• Buffer concentration
• Plasticizer level
• Cutting and packaging conditions

A developer should target a narrow dissolution profile across dose strengths. Scaling from the 2 mg/0.5 mg strength to the 8 mg/2 mg strength can change film area, thickness, drug loading, and dissolution kinetics.

2. Manage taste and local tolerability

Buprenorphine and naloxone can produce bitter, acidic, or metallic taste perceptions. Taste masking is commercially important because treatment is often chronic and adherence depends on tolerability.

The lowest-risk approach is usually a combination of:

• High-intensity sweetener
• Controlled flavor system
• Buffer optimization
• Reduced exposure of free drug particles
• Polymer entrapment or matrix dispersion
• Limited use of complexing agents that could alter absorption

Strongly hydrophobic coatings or ion-exchange systems may improve taste but can delay sublingual release and complicate bioequivalence. Excessive flavoring can also cause mucosal irritation or create regulatory questions regarding local tolerability.

3. Protect against moisture

Film products are sensitive to humidity because water can change tensile strength, tack, dissolution, and drug distribution. Individual foil pouches are therefore a major part of the product system.

Commercially relevant moisture-control measures include:

• High-barrier foil laminate
• Low-water-activity excipient grades
• Controlled drying conditions
• In-process humidity control
• Low-residual-solvent manufacturing
• Desiccant-equipped secondary packaging where appropriate

Maltitol and other polyols can improve mouthfeel but may increase hygroscopicity. The developer must evaluate equilibrium moisture, glass-transition behavior, and package integrity together rather than optimizing the film alone.

4. Maintain dose uniformity

The drug load is low relative to the total film or tablet mass. Content uniformity depends on drug dispersion, suspension stability, mixing order, viscosity, drying rate, and cutting precision.

For film manufacturing, the highest-risk steps are:

1. Drug dispersion in the polymer solution or suspension
2. Casting or coating at constant wet thickness
3. Drying without migration of either active ingredient
4. Slitting and dose cutting
5. Pouch filling without edge damage

A well-designed formulation uses excipients that maintain a stable drug distribution during drying. Excessive viscosity can reduce coating uniformity. Low viscosity can allow sedimentation or drug migration.

5. Control salt and hydrate behavior

Buprenorphine hydrochloride and naloxone hydrochloride dihydrate require defined controls for:

• Water content
• Polymorphic or pseudopolymorphic form
• Assay conversion to active-base equivalents
• Hygroscopicity
• Particle-size distribution
• Residual solvents
• Elemental impurities
• Microbial quality

Naloxone hydrochloride dihydrate can lose or gain water during storage and processing. The specification should control hydrate state through raw-material testing and finished-product stability rather than relying only on nominal weighing.

What formulation patents protect buprenorphine and naloxone products?

The most commercially relevant patent protection has historically focused on the Suboxone film composition, manufacturing process, dosage form, and methods of treating opioid dependence.

Patent or patent family	Subject matter	Commercial relevance
U.S. Patent No. 8,017,150	Buprenorphine/naloxone dosage-form technology associated with Suboxone	Earlier protection; expiration and enforceability depend on term adjustments and litigation history
U.S. Patent No. 8,603,514	Sublingual film composition and related product claims	Central to historical generic-film litigation
Related Indivior patent families	Film architecture, dosage strength, manufacturing, and use	Potential barriers vary by jurisdiction and claim scope

Indivior’s film patent strategy generated extensive litigation against generic applicants. In 2019, the U.S. District Court for the District of Delaware held key claims of U.S. Patent No. 8,603,514 invalid for obviousness. The Federal Circuit later affirmed the invalidity ruling.[4,5]

The practical result is that the principal formulation patent barrier to generic Suboxone film entry was materially weakened. Remaining risk can arise from other listed patents, patent-term adjustments, pediatric extensions, regulatory exclusivity, confidential manufacturing know-how, and state or federal product-liability exposure.

What is the Orange Book status of buprenorphine/naloxone?

The FDA Orange Book identifies patents and exclusivity associated with approved drug products. For buprenorphine/naloxone, the Orange Book is most important for:

• NDA 022410 for Suboxone film
• NDA 020733 for earlier Suboxone tablet products
• NDA 204242 for Zubsolv
• Patent listings relevant to ANDA Paragraph IV certifications
• Pediatric exclusivity and patent-term extensions, if applicable

An ANDA applicant must address each listed patent through a Paragraph I, II, III, or IV certification. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Patent litigation can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.[6]

The Orange Book should be reviewed at the time of filing and before launch because listing status, patent delistings, litigation outcomes, and exclusivity dates can change. Patent expiration alone does not eliminate regulatory or manufacturing barriers.

When does buprenorphine/naloxone lose exclusivity?

The commercial loss of exclusivity occurred in stages rather than on a single date.

Exclusivity component	General status
Original Suboxone tablet protection	Largely expired before the film market matured
Suboxone film formulation patents	Subject to major Paragraph IV litigation and invalidity rulings
FDA orphan exclusivity	Not the primary commercial protection for this product
Regulatory exclusivity	Separate from patent protection and dependent on the applicable NDA history
Generic film entry	Began after ANDA approvals and litigation developments
Current competitive barrier	Manufacturing quality, physician substitution, patient retention, packaging, and supply reliability

The product category is therefore a post-exclusivity market in which formulation execution and commercial access are more important than a single blocking patent.

Which companies are challenging or competing with Suboxone?

Competition includes generic manufacturers, branded tablet suppliers, and alternative buprenorphine products.

Competitor group	Examples	Competitive basis
Generic film manufacturers	Dr. Reddy’s Laboratories and other ANDA holders	Price, pharmacy coverage, supply
Generic tablet manufacturers	Multiple ANDA sponsors	Lower manufacturing complexity and cost
Branded tablet products	Zubsolv	Taste, tablet size, dissolution, prescriber loyalty
Long-acting products	Sublocade, Brixadi	Reduced daily dosing and diversion-control advantages
Methadone providers	Opioid-treatment programs	Different regulatory and clinical model
Compounded or institutional products	Limited settings	Local supply or specialized use

The principal substitution risk for a new buprenorphine/naloxone product comes from generic film and tablet products, not biosimilars. This is a small-molecule combination, so the FDA pathway is ANDA or, for a differentiated product, potentially 505(b)(2). A biosimilar pathway does not apply.

What commercial opportunities exist for new excipient systems?

Generic sublingual film

The most direct opportunity is an ANDA-compliant film with:

• Lower cost of goods
• Stable two- to three-year shelf life
• High film yield
• Strong package integrity
• Comparable pharmacokinetics
• Acceptable taste
• Reliable pharmacy supply

A generic sponsor should avoid unnecessary excipient innovation when the target is an ANDA. New excipients or materially different excipient levels may create additional safety and bioequivalence work.

Differentiated 505(b)(2) product

A 505(b)(2) product can support meaningful formulation changes, such as:

• Faster dissolution
• Improved taste
• Smaller dosage unit
• Longer mucosal residence
• Alternative buccal placement
• Improved moisture resistance
• Child-resistant unit-dose packaging
• Lower naloxone exposure under intended use with preserved misuse deterrence

The commercial value depends on whether the change improves adherence, reduces administration errors, or earns payer and prescriber preference. A minor excipient change without a measurable patient or manufacturing benefit is unlikely to justify 505(b)(2) development cost.

Abuse-deterrent and diversion-control designs

The buprenorphine/naloxone combination already has a misuse-deterrent rationale, but a new dosage form could improve resistance to:

• Dissolution and injection
• Crushing
• Film extraction
• Dose splitting
• Accidental pediatric exposure
• Unauthorized transfer

Any abuse-deterrent claim requires robust comparative testing and careful labeling analysis. The formulation should not compromise sublingual release or create a higher risk of accidental ingestion.

Pediatric and specialty packaging

The product is used in a population with significant diversion and accidental-exposure concerns. Commercial opportunities include:

• Individually sealed unit doses
• Tamper-evident cartons
• Calendarized packaging
• Improved opening systems
• Packaging that limits exposure to children
• Pharmacy-specific dispensing formats

Packaging improvements can be protected through utility or design patents even when the active formulation is no longer strongly protected.

Geographic expansion

The combination has global potential, but regulatory and commercial requirements differ by jurisdiction. Key issues include:

• Controlled-substance scheduling
• National substitution rules
• Local requirements for opioid-dependence treatment
• Approved dosage forms
• Stability zones
• Language and packaging requirements
• Government procurement and tender pricing

Film products may have advantages where unit-dose dispensing and portability are valued. Tablets may have lower manufacturing and shipping costs in price-sensitive markets.

How strong is the patent estate for a new buprenorphine/naloxone product?

The estate is strongest when it combines formulation claims with manufacturing, packaging, and method-of-use claims. A new entrant relying only on the active combination has limited protection because the combination is established and generic competition exists.

A stronger strategy can include:

• Polymer ratio and film-thickness claims
• Defined dissolution windows
• Moisture-activity limits
• Taste-masking systems
• Manufacturing controls that reduce drug migration
• Unit-dose package architecture
• Stability claims tied to hydrate control
• Patient-use methods that reduce swallowing or administration errors

The enforceability of formulation claims depends on whether the claims cover commercially necessary features. Narrow claims that competitors can design around provide limited value. Claims tied to measurable performance, such as dissolution, tensile strength, residual moisture, or content-uniformity ranges, can be more commercially relevant but require strong analytical support.

What generic launch risks exist?

The principal risks are regulatory, supply-chain, and commercial.

Risk	Effect on launch
Paragraph IV litigation	Approval delay, legal expense, launch uncertainty
Failure to demonstrate bioequivalence	Additional studies or reformulation
Taste dissatisfaction	Lower adherence and prescriber acceptance
Film cracking or pouch failure	Recalls, yield loss, supply interruptions
API hydrate variability	Assay and stability failures
Inadequate dissolution matching	ANDA deficiency or clinical concern
Controlled-substance compliance	Manufacturing and distribution restrictions
Price erosion	Lower return on development investment
Limited pharmacy substitution	Slower uptake despite approval

The best generic opportunity is a product with a simple excipient system, proven packaging, broad API sourcing, and a bioequivalence plan aligned with FDA product-specific guidance.[7]

How does buprenorphine/naloxone compare with long-acting buprenorphine?

Attribute	Sublingual buprenorphine/naloxone	Long-acting buprenorphine injection
Dosing	Daily or frequent administration	Weekly or monthly
Administration	Patient-administered	Healthcare-provider administered
Excipient focus	Taste, dissolution, adhesion, moisture	Depot formation, release control, injection tolerability
Diversion risk	Ongoing take-home exposure	Lower take-home diversion risk
Manufacturing	Film casting or tablet compression	Sterile injectable manufacturing
Regulatory route for new product	ANDA or 505(b)(2)	505(b)(2), NDA, or other applicable pathway
Commercial barrier	Generic price competition	Injectable manufacturing and clinical infrastructure

Sublingual products remain attractive because they have lower development and manufacturing barriers than sterile long-acting injections. Long-acting products, however, can command greater value through reduced dosing frequency and supervised administration.

What licensing and partnership opportunities exist?

Licensing opportunities are most credible in four areas:

1. Proprietary film platforms with validated opioid-delivery performance
2. Taste-masking and mucosal-adhesion technologies
3. High-barrier packaging and controlled-substance dispensing systems
4. Regional commercialization rights in regulated opioid-treatment markets

A pharmaceutical company may license an excipient platform while retaining the active-product application. A generic manufacturer may prefer a manufacturing or supply agreement that reduces development time without creating a dependence on a single proprietary polymer or flavor system.

The most valuable deal terms are likely to concern territory, exclusivity, minimum purchase commitments, regulatory ownership, technical-transfer obligations, and rights to improvements. For a mature combination product, manufacturing reliability and market access generally carry more value than broad but weak formulation claims.

Key Takeaways

• Buprenorphine hydrochloride and naloxone hydrochloride dihydrate is a mature small-molecule combination with no biosimilar pathway.
• Sublingual films rely on polymer selection, moisture control, taste masking, and precise dose cutting.
• Tablet products offer simpler manufacturing but compete on rapid disintegration, taste, tablet size, and cost.
• The Suboxone film patent estate was materially weakened by Paragraph IV litigation and invalidity rulings involving U.S. Patent No. 8,603,514.
• The strongest new-product opportunities are generic films, differentiated 505(b)(2) dosage forms, abuse-deterrent systems, and high-control packaging.
• Naloxone hydrate control, sublingual dissolution, film uniformity, and foil-pouch integrity are core technical risks.
• Commercial success depends on price, pharmacy substitution, patient tolerability, supply reliability, and controlled-substance compliance.
• A defensible follow-on estate should combine formulation, manufacturing, packaging, and measurable performance claims.

FAQs

Is naloxone hydrochloride dihydrate necessary in a sublingual buprenorphine product?

Naloxone is not required for buprenorphine pharmacologic activity, but it is included to discourage injection and other non-prescribed routes of use. The hydrate form is relevant to assay, water content, and stability control.

Can a company use different excipients in a generic Suboxone film?

Yes. An ANDA applicant can use a different excipient system if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, safety, and labeling requirements. Material formulation differences can increase development and regulatory risk.

Which excipient is most important for sublingual film performance?

No single excipient controls performance. The polymer system, plasticity, buffer, sweetener, drug dispersion, drying process, and package barrier operate as an integrated system.

Is a buprenorphine/naloxone film eligible for a biosimilar application?

No. Buprenorphine and naloxone are small molecules. A generic product normally proceeds through an ANDA, while a materially differentiated product may use a 505(b)(2) application.

What is the most attractive commercial niche for a new product?

A differentiated sublingual film with improved taste, consistent rapid dissolution, robust moisture stability, and child-resistant unit-dose packaging offers the clearest opportunity beyond low-price generic competition.

References

1. U.S. Food and Drug Administration. (2023). Suboxone (buprenorphine and naloxone) sublingual film prescribing information.
2. U.S. Food and Drug Administration. (2023). Zubsolv (buprenorphine and naloxone) sublingual tablets prescribing information.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: Zubsolv application no. 204242.
4. Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., 930 F.3d 1325 (Fed. Cir. 2019).
5. U.S. District Court for the District of Delaware. (2019). Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., patent invalidity proceedings concerning U.S. Patent No. 8,603,514.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. U.S. Food and Drug Administration. (2023). Product-specific guidance for buprenorphine hydrochloride; naloxone hydrochloride sublingual film.